Overall Survival of Papillary Thyroid Carcinoma Patients: A Single-Institution Long-Term Follow-Up of 5897 Patients

Yasuhiro Ito, Akira Miyauchi, Minoru Kihara, Mitsuhiro Fukushima, Takuya Higashiyama, Akihiro Miya, Yasuhiro Ito, Akira Miyauchi, Minoru Kihara, Mitsuhiro Fukushima, Takuya Higashiyama, Akihiro Miya

Abstract

Introduction: Papillary thyroid carcinoma (PTC) generally shows an excellent prognosis except in cases with aggressive backgrounds or clinicopathological features. Although the cause-specific survival (CSS) of PTC patients has been extensively investigated, the overall survival (OS) of these patients is unclear. We herein investigated both the OS and CSS of a large PTC patient series.

Materials and methods: We enrolled 5897 PTC patients who underwent initial surgery between 1987 and 2005 (658 males and 5339 females; median age 51 years). Their median postoperative follow-up period was 177 months. Univariate and multivariate analyses for OS and CSS assessed the effects of gender, older age (≥55 years), distant metastasis at diagnosis (M1), significant extrathyroid extension, tumor size (cutoffs 2 and 4 cm), large node metastasis (N ≥ 3 cm), and extranodal tumor extension.

Results: To date, 387 patients (7%) in this series have died from various causes, including 117 (2%) due to PTC. The 10-, 15-, and 20-year OS rates are 97, 95, and 90%, respectively. Older age and M1 were important prognostic factors for OS and CSS. Older age was a more significant factor than M1 for OS and vice versa for CSS. In the older patients, M1 was a prominent prognostic factor for both OS and CSS. In the young patients, M1 had less prognostic impact than in the older patients, and the prognostic values of M1 and N ≥ 3 cm for OS and CSS were identical and similar, respectively.

Conclusions: The most important prognostic value for OS was patient age, indicating that PTC is generally indolent. However, the control of distant metastasis in older patients remains a future challenge in order to further improve their OS and CSS. PTC of ≥3 cm in young patients should be carefully followed, even in the absence of metastases, and these patients should undergo aggressive therapies for recurrent lesions and metastases.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve of OS in the entire series of patients
Fig. 2
Fig. 2
Kaplan–Meier curve of CSS in the entire series of patients

References

    1. Cady B, Rosai R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953.
    1. Hay ID, Bergstrahl EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1058.
    1. American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th edn. 10.1007/978-3-319.40618.3.73
    1. Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg. 2012;36:1274–1278. doi: 10.1007/s00268-012-1423-5.
    1. Ito Y, Kudo T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Prognostic factors of papillary thyroid carcinoma vary according to sex and patient age. World J Surg. 2011;35:2584–2590. doi: 10.1007/s00268-011-1327-9.
    1. Ito Y, Miyauchi A, Kudo T, Kihara M, Fukushima M, Miya A. The effectiveness of prophylactic modified neck dissection for reducing the development of lymph node recurrence of papillary thyroid carcinoma. World J Surg. 2017
    1. Uruno T, Miyauchi A, Shimizu K, Tomoda C, Takamura Y, Ito Y, et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg. 2005;29:483–485. doi: 10.1007/s00268-004-7701-0.
    1. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139–148. doi: 10.1016/S0039-6060(03)00384-2.
    1. Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen HB, Hahn CH, et al. Papillary thyroid carcinoma in Denmark, 1996-2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid. 2015;25:78–84. doi: 10.1089/thy.2014.0294.
    1. Lo TE, Canto AU, Maningat PD. Risk factors for recurrence in Filipinos with well-differentiated thyroid cancer. Endocrinol Metab. 2015;30:543–550. doi: 10.3803/EnM.2015.30.4.543.
    1. Krook KA, Fedewa SA, Chen AY. Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment. Laryngoscope. 2015;125:1021–1027. doi: 10.1002/lary.25017.
    1. Zhang W, Jiao D, Liu B, Sun S. Analysis of risk factors contributing to recurrence of papillary thyroid carcinoma in Chinese patients who underwent total thyroidectomy. Med Sci Monit. 2016;22:1274–1279. doi: 10.12659/MSM.895564.
    1. Su DH, Chang SH, Chang TC. The impact of locoregional recurrences and distant metastases on the survival of patients with papillary thyroid carcinoma. Clin Endocrinol. 2015;82:286–294. doi: 10.1111/cen.12511.
    1. Ito Y, Ichihara K, Masuoka H, Fukushima M, Inoue H, Kihara M, et al. Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg. 2010;34:2570–2580. doi: 10.1007/s00268-010-0710-2.
    1. Ito Y, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Clinical outcomes of patients with papillary thyroid carcinoma after the detection of distant recurrence. World J Surg. 2010;34:2333–2337. doi: 10.1007/s00268-010-0712-0.
    1. Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, et al. Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr J. 2010;57:523–531. doi: 10.1507/endocrj.K10E-019.
    1. Brose MS, Nutting CM, Jaerzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014;384:319–328. doi: 10.1016/S0140-6736(14)60421-9.
    1. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–630. doi: 10.1056/NEJMoa1406470.
    1. Brose MS, Worden FP, Newboid KL, Guo M, Hurria A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SLECT trial. J Clin Oncol. 2017;35:2692–2699. doi: 10.1200/JCO.2016.71.6472.
    1. Ito Y, Miyauchi A, Kudo T, Kihara M, Fukushima M, Miya A. The effectiveness of prophylactic modified neck dissection for reducing the development of lymph node recurrence of papillary thyroid carcinoma. World J Surg. 2017;41:2283–2289. doi: 10.1007/s00268-017-4023-6.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться